Defects in Niemann-
INTRODUCTION
Through studies of humans with inborn errors of metabolism, scientists have uncovered many aspects of lipid biochemistry (1) (2) (3) . One disorder that remains puzzling is the complex disease known as Niemann-Pick, Type C, which is caused by loss-of-function mutations in one of two different genes, NPC1 and NPC2 2 (4) . The clinical spectrum in patients with this lipid storage disorder is wide. Most subjects manifest in childhood with a devastating syndrome that includes enlargement of liver and spleen, lung disease, and neurological degeneration manifested by ataxia, dysarthria, gaze palsies, and progressive dementia, usually resulting in death before age 20 (5) . The liver and spleen accumulate unesterified cholesterol, sphingomyelin and a variety of phospholipids and glycosphingolipids. Brain tissue does not contain a gross excess of cholesterol or sphingomyelin, but there is a distinct elevation of glycosphingolipids (5) . Recent studies of a mouse model of NPC1 disease indicate that neurons may accumulate excess cholesterol, but this accumulation is masked at a gross level by a decline in the amount of cholesterol in myelin (6) .
Despite the wide variety of lipid abnormalities in organs of these patients, the functional abnormality in cultured fibroblasts is surprisingly simple (7) . These cells exhibit a striking defect in the disposal of cholesterol that has entered the cell through receptor-mediated endocytosis initiated by binding to low density lipoprotein (LDL) receptors. After uptake in coated vesicles, ingested LDL is delivered to lysosomes where the cholesteryl esters, which constitute the bulk of its cholesterol, are hydrolyzed. The unesterified cholesterol exits the lysosome and is transported to other organelles, including the endoplasmic reticulum (ER), where the cholesterol exerts two regulatory actions that maintain cholesterol homeostasis: 1) it blocks the ER exit and subsequent proteolytic activation of sterol regulatory element-binding proteins (SREBPs), which are transcription factors that increase cholesterol synthesis (8) , and 2) it activates acyl CoA: cholesterol acyltransferase (ACAT), an enzyme that re-esterifies cholesterol for storage as cytoplasmic cholesteryl ester droplets (9, 10) . In fibroblasts from NPC patients, LDL enters cells normally, and the cholesteryl esters are hydrolyzed in lysosomes, but the liberated cholesterol remains trapped as free cholesterol in lysosomes. As a result of this exit block, LDLderived cholesterol fails to inhibit SREBP processing (11) , and it fails to activate ACAT (7, 12) . A similar defect occurs in fibroblasts from BALB/c npc nih mice, a line of mice with an NPC phenotype (13) , and in CT60 cells, a line of cultured Chinese hamster ovary (CHO) cells that were mutagenized and selected to have a defect in cholesterol release from lysosomes (14) .
A major advance in understanding of NPC disease occurred when the first defective gene was identified by positional cloning (15) . This gene encodes a 1278-amino acid integral membrane protein, now known as NPC1, that resides in late endosomes and lysosomes of cultured cells. Mutations in the murine version of NPC1 are responsible for the defect in BALB/c npc nih mice, and the hamster version is defective in CT 60 cells.
Evidence indicates that NPC1 is a polytopic membrane protein with 13 membranespanning helices (16) . The protein has a cleaved NH 2 -terminal signal sequence that targets the protein for insertion into membranes, three large luminal loops, and a cytoplasmic COOHterminal segment that includes a dileucine sequence that targets the protein to lysosomes (17) .
Helices 3-7 of mature NPC1 bear sequence homology to a sterol-sensing sequence that was found initially in Scap, a sterol-sensing protein of the ER (18) . Similar sequences are found in the ER enzyme 3-hydroxy-3-methylglutaryl coenzyme A reductase (19) and in Patched, a receptor for Hedgehog, a protein morphogen that bears a covalently attached cholesterol moiety (18, 20) . In Scap, this sequence was named the sterol-sensing domain (19) , and it has been shown to bind cholesterol (21, 22) . Whether this sequence in the other proteins binds cholesterol or other sterols is unknown.
Approximately 5-10% of patients with NPC disease have a mutation in NPC2, a soluble protein that is partially sequestered in lysosomes, and partially secreted by cells (23) . Cultured cells from subjects with NPC2 deficiency have the same defect in release of lysosomal cholesterol as do cells with an NPC1 mutation (24) . NPC2 has been demonstrated to bind cholesterol (25) (26) (27) (28) , and a crystal structure of NPC2 with bound cholesterol sulfate has been solved (29) . The similarity in phenotypes between NPC1 and NPC2 mutations strongly suggests that the two proteins function sequentially in a pathway that releases cholesterol from lysosomes, but the order of their actions has not been determined (30) .
As described in the accompanying paper (11), we encountered NPC1 unexpectedly in a search for a membrane-bound protein that binds oxysterols such as 25-hydroxycholesterol (25-HC). When delivered to cells in ethanol, these oxysterols mimic the ER regulatory actions of cholesterol, i.e., they block SREBP cleavage and they activate ACAT (8, 11) .
However, oxysterols do not traverse lysosomes, and there is no evidence that they require the actions of NPC1 or NPC2 in order to reach the ER. We were therefore surprised to find that a purified membrane-bound, oxysterol-binding protein turned out to be NPC1. In further studies we showed that recombinant human NPC1 bound cholesterol as well as oxysterols, but cholesterol binding occurred only when the detergent concentration was reduced below micellar levels (11) .
In the current studies we localize the sterol binding site in human NPC1 to luminal loop-1. Using recombinant DNA technology, we prepare luminal loop-1 as a soluble protein of 240 amino acids that is secreted by cells. Purified luminal loop-1 binds oxysterols and cholesterol with high affinity. We characterize this binding reaction and provide evidence that luminal loop-1 contains the majority, if not all, of the cholesterol binding activity of NPC1. cholesteryl sulfate from Sigma; n-dodecyl-β-Dmaltopyranoside (DDM) and CHAPS from Anatrace, Inc.; and bovine serum albumin (BSA) from Pierce (Cat. No. 23210). Radioisotopes, antibodies, sterols, chromatographic supplies, lipoproteins, lipoprotein-deficient serum (LPDS), and all other reagents (unless otherwise specified) were obtained from sources prepared as described in the accompanying paper (11) .
Buffers − Buffer A contains 50 mM Tris-chloride at pH 7.4, 150 mM NaCl, and 0.004% (w/v) NP-40. Buffer B contains 50 mM Tris-chloride at pH 7.4, 100 mM KCl, and 1% NP-40. Buffer C contains 50 mM Tris-chloride at pH 7.4 and 150 mM NaCl. Buffer D contains 50 mM Tris-chloride at pH 7.4, 50 mM KCl, 10% (v/v) glycerol, 5 mM dithiothreitol, 1 mM sodium EDTA, and protease inhibitor mixture (1 μg/ml pepstatin A, 2 μg/ml aprotinin, 10 μg/ml leupeptin, 200 μM phenylmethylsulfonyl fluoride, and 25 μg/ml of N-acetyl-leucinalleucinal nonleucinal).
Plasmid Constructions − pCMV-NPC1-His 8 -Flag encodes wild-type human NPC1 followed sequentially by eight histidines and a Flag tag under control of the cytomegalovirus (CMV) promoter. This plasmid was constructed as described in the accompanying paper (11) . pCMV-NPC1(1-307;1254-1278)-His 8 -Flag was constructed from pCMV-NPC1-His 8 -Flag by site-directed mutagenesis (QuickChange II XL kit, Stratagene) using the 5'-oligonucleotide, 5′-CTCCGAGTACACTCCCATCGATAGC GTAAATAAAGCCAAAAGTTGTGCC-3′ and the 3'oligonucleotide, 5′-GGCACAACTTTTGGCTTTATTTACGC TATCGATGGGAGTGTAGTCGGA-3′. pCMV-NPC1(1-264)-His 8 -Flag was constructed from pCMV-NPC1(1-307;1254-1278)-His 8 -Flag by site-directed mutagenesis using the 5′oligonucleotide, 5′-CCTGCTCCCTGGACGA TCCTTGGCCATCACCATCACCATCACCAT CACGACTAA-3′ and the 3'oligonucleotide, 5′-TTATAGTCGTGATGGTGATGGTGATG GTGATGGCCAAGGATCGTCCAGGGAGCA GG-3′. The coding region of each plasmid was sequenced to ensure integrity of the construct. Mutations in NPC1 were produced by sitedirected mutagenesis of pCMV-NPC1(1-264)-His 8 -Flag and pCMV-NPC1-His 8 -Flag plasmids.
pCMV-NPC2-His 8 encodes wild-type human NPC2 followed sequentially by eighthistidines under control of the CMV promoter. (Fisher Scientific) . After 24 h, the medium was collected and fresh medium A containing 1% Cellgro® ITS was added. This was done for 3 consecutive days for each group of transfected cells. After each collection, the medium was subjected to centrifugation at 2,500 rpm for 5 min at 4°C and then filtered through an Express PLUS 0.22-μm filter apparatus (Millipore). Medium was stored at 4°C covered in aluminum foil. Gravity columns were each filled with a 20-ml slurry of Ni-NTA agarose beads, after which each column was pre-equilibrated with 4 column volumes of buffer C. Filtered medium (1 L per column) was then passed overnight at 4°C through each Ni-NTA agarose column ~1 ml/min. Each column was washed sequentially with 50 ml of buffer C containing 20 mM and 40 mM imidazole. Bound protein was eluted with 50 ml of buffer C containing 200 mM imidazole. The eluted fraction containing NPC1(25-264)-His 8 -Flag or NPC2-His 8 was concentrated to 0.5 ml by using a spin concentrator with an Amicon Ultracel 30K or 10K Filter Device (Millipore), respectively. The concentrated material was then subjected to gel filtration chromatography on a 24-ml Superdex-200 column that was preequilibrated with buffer C.
The fractions containing the peak A 280 activity and eluting between 12.5 and 15 ml (for NPC1 (25- 3 H-sterol concentration, 10-400 nM), 1 μg of BSA as indicated, and varying amounts of NPC1 or NPC2 protein. After incubation for 4 h or 16 h at 4°C, the mixture was loaded onto a column packed with 0.3 ml of Ni-NTA Agarose beads (Qiagen) that had been pre-equilibrated with the appropriate assay buffer. Each column was washed for ~ 15 min with 5-6 ml of buffer B, except for the experiments described in Fig. 6 . The proteinbound 3 H-sterol was eluted with 250 mM imidazole in buffer B and quantified by scintillation counting as previously described (Radhakrishnan et al., 2004) . For competition experiments with unlabeled sterols, the standard assays were carried out in the presence of the indicated unlabeled sterol (0-3 μM) delivered in ethanol (final ethanol concentration, 1-4%). In each experiment, all tubes received the same amount of ethanol.
Glycosidase Treatments − Each reaction, in a final volume of 42 μl, was carried out according to the manufacturer's directions (New England BioLabs) for 16 h at 37°C with the indicated amount of purified protein in the presence or absence of 4000 units of Endo H or 5000 units of peptide N-glycosidase F (PNGase F).
SREBP-2 Processing in Cultured Cells
were transfected as described above. On day 3, the medium was switched to medium A containing 5% newborn calf LPDS, 5 µM compactin, and 50 µM sodium mevalonate. On day 4, the cells received fresh medium A supplemented with 5% newborn calf LPDS and various concentrations of β-VLDL or 25-HC. After incubation at 37°C for 5 h, cells were treated with 25 µg/ml of N-acetyl-leucinalleucinal-norleucinal for 1 h and then harvested. Duplicate dishes were pooled for preparation of nuclear extract and 100,000g membrane fractions, which were then analyzed by immunoblotting for SREBP-2 (described below).
Immunoblot Analysis -The procedure for immunoblot analysis and the concentrations of antibodies used are exactly as described in the accompanying paper (11) except for the use of one additional antibody.
Epitope-tagged SREBP-2 was detected with 0.2 µg/ml of IgG-HSV-Tag™, a monoclonal antibody directed against the glycoprotein D epitope of Herpes simplex virus (Novagen, Inc).
ACAT Assay − Fig. 1A shows a diagram of the postulated domain structure of human NPC1, a 1278-amino acid protein.
RESULTS

Localization of Oxysterol Binding Site in NPC1 -
The protein is believed to contain 13 putative transmembrane helices (16) (17) .
To localize the region in NPC1 that binds 25-HC, we created plasmids encoding the first 307, 644, 809, or 1178 amino acids of the protein fused to a fragment comprising the COOH-terminal 24 amino acids, which contains the lysosomal targeting signal. The epitopetagged proteins were purified as described for the full length protein in the accompanying paper (11) . All of these internally deleted proteins bound [ (Fig. 1D) . The binding specificity of the internally deleted NPC1 with respect to oxysterols is thus similar to that of the fulllength molecule (11) .
Secretion and Purification of Luminal Loop-1 of NPC1 -In order to further define the oxysterol-binding site within the membraneanchored, internally deleted NPC1(1-307;1254-1278), we made a further truncation from the COOH-terminus to remove the single transmembrane domain and the lysosomal targeting sequence. This protein, designated NPC1(25-264)-His 8 -Flag, contains the signal sequence and luminal loop-1 as shown in Fig.  2A . Fig. 2B shows a comparison of the amino acid sequence of luminal loop-1 of human NPC1 with a consensus sequence that was derived from the sequences of 12 vertebrate species, including 10 mammals. Of the 240 amino acids in this domain, 124 are invariant (Fig. 2B, black  boxes) . Eighteen of the invariant residues are cysteines (Fig. 2B, yellow boxes) . The 12 vertebrate sequences are shown in Fig. 1SM .
When expressed in CHO cells by transfection, full-length NPC1-His 8 -Flag and NPC1(1-307;1254-1278)-His 8 -Flag were found exclusively in a 10 5 g pellet of cell membranes (Fig. 2C, lanes 6 and 9) . In contrast, the vast bulk of NPC1(25-264)-His-Flag was secreted into the medium (lane 10). Note that the relative amount of the medium fraction applied to the gel was only one-fifth the amount of the cell supernatant and pellet fractions.
To purify luminal loop-1 from the medium of transfected CHO cells, the medium was subjected to Ni-chromatography followed by gel filtration chromatography in the absence of detergents (see "Experimental Procedures"). When stored at 4°C in buffer C (without detergent) at concentrations between 0.3-2.0 mg/ml, the protein retained full binding activity and continued to appear monodisperse on gel filtration. The calculated molecular mass for the protein component of the epitope-tagged luminal loop-1 is 28.7 kDa. However, the secreted protein migrated on SDS-PAGE as a diffuse band slightly above the 50-kDa marker (Fig. 3A,  lane 1) . Treatment of the secreted protein with the glycosidase PNGaseF under denaturing conditions caused the recombinant protein to migrate as a compact band close to the 30-kDa marker (data not shown). Thus, the diffuse migration is attributable to glycosylation of some or all of the 5 potential N-linked glycosylation sites in the loop (Fig. 2B) . Upon gel filtration in the absence of detergents, this protein eluted as a single symmetrical peak corresponding to ~100 kDa (Fig. 3B ). We believe that the 100-kDa species is a dimer. When the protein was analyzed by circular dichroism (Fig. 3C) , it showed a spectrum characteristic of high α-helical content with minima at 207 and 222 nm (34, 35) .
Binding Specificity of Luminal Loop-1 -To measure the binding of slightly higher than the critical micellar concentration (CMC), which is 0.0015% (discussed below). Fig. 4A 4A) and by similar concentrations of unlabeled 24-HC and 27-HC (see Fig. 7G ).
We (Fig. 5B) . The CMC for each detergent was determined by a dye encapsulation method (36) under conditions that were identical to those of our binding assay, i.e., in buffer C at 4°C. Binding of [ 3 H]cholesterol was intact at the submicellar concentrations of all four detergents examined (NP-40, DDM, DHPC, and CHAPS). In each case, binding was markedly reduced at supramicellar detergent concentrations. This relationship held even though the CMC values for these four detergents varied over a range of nearly 100-fold (0.0015% for NP-40 to 0.2% for CHAPS). On the other hand, [ 3 H]25-HC was unaffected by the detergents except for CHAPS, which reduced binding at a concentration that was 6-fold above the CMC (Fig. 5B) .
Mutational homologs of NPC1 found in 76 eukaryotic species (data not shown). These residues were also chosen for their hydrogen-bonding potential (Q79, N103, and Q117) or for their ability to form ring-stacking interactions (F120 and Y157). Each of these residues was mutated to alanine (see Fig. 2C, red boxes) . The two hydrophobic residues, F120 and Y157, were also mutated to methionine. In addition to these novel mutations, we reproduced six "clinical" mutations corresponding to substitutions in luminal loop-1 observed in patients with NPC1 disease (Q92R, T137M, P166S, N222S, D242H, and G248V; see Fig. 2C , blue boxes) (37) . Plasmids encoding each mutant version of luminal loop-1 were expressed in CHO cells, and the recombinant proteins were purified from the medium in a similar manner to the wild-type version. All mutant proteins were secreted, and they all showed a normal behavior on gel filtration and SDS-PAGE. The data for the Q79A mutant is shown in Fig. 3 (Fig. 6B) . Similar results were obtained in 4 additional experiments involving 3 different preparations of purified luminal loop-1. Circular dichroism (CD) spectra of the Q79A protein was identical to that of the wild-type protein, indicating no major structural changes (Fig. 3C) Pick, Type C disease harbor mutations in NPC2, a soluble 132-amino acid protein that is secreted into plasma and also resides within the cell, primarily in lysosomes (23) . Previous studies have shown that NPC2 binds cholesterol with measured K d values that range from 50 nM to 5 μM in different laboratories (25) (26) (27) .
To compare the sterol binding properties of NPC1 and NPC2, we prepared a plasmid encoding pCMV-NPC2-His 8 , expressed it in CHO cells, and purified the secreted NPC2 using the same procedure as described for luminal loop-1 of NPC1. The calculated molecular mass of the secreted protein component of NPC2-His 8 is 15.7 kDa.
However, purified NPC2-His 8 migrated on SDS-PAGE as 3 distinct bands (23, 21 , and 18 kDa) as visualized by Coomassie staining (Fig. 7A) . Previous studies showed that NPC2 contains three N-linked carbohydrate chains that contain mannose-6-phosphate (38) . Treatment of purified NPC2-His 8 with the glycosidase endo H (which removes only highmannose chains) reduced the molecular mass of band 2 from 21 to 19 kDa and band 3 from 18 to 16 kDa (Fig. 7A ), whereas treatment with PNGase F (which removes all N-linked chains) reduced all 3 bands to the predicted protein molecular mass of 16 kDa (Fig. 7A) . Gel filtration studies of the recombinant NPC2 showed that it eluted as a single symmetrical peak corresponding to ~20 kDa (data not shown 7B) .
Competitive binding studies confirmed that NPC2-His 8 binds cholesterol but not 25-HC (Fig. 7D) , two other iso-octyl oxysterols, 24-HC and 27-HC (Fig. 7F) or NPC2 when tested at concentrations up to 3 μM (data not shown). These results are consistent with the recent studies of Liou, et al. (39) , who assessed the sterol-binding specificity of NPC2 with a competition assay in which the labeled ligand was a fluorescent plant sterol (i.e., dehydroergosterol) and the competitor unlabeled sterols were each tested at a single concentration. The most effective competitor was cholesteryl sulfate (100% inhibition), whereas the iso-octyl oxysterols showed either no competitive inhibition (25-HC) or a partial inhibition of ~35% (24-HC and 27-HC).
Sterol Binding Properties of Full-length Mutant NPC1(Q79A) − To determine whether the point mutation Q79A that disrupts 25-HC binding in luminal loop-1 of NPC1 also affects the binding properties of the full-length NPC1 molecule, we expressed and purified the Q79A mutant version of full-length NPC1-His 8 -Flag in 0.004% NP-40 as described for the wild-type protein in the accompanying paper (11) . As shown in the binding curves in Fig. 8A (31) . Figure 9A (Fig. 9B) .
In wild-type cells, when cholesterol derived from β-VLDL reaches the ER, it prevents the exit of SREBP-2, thereby blocking its proteolytic processing (8) .
In mocktransfected CHO 4-4-19 cells, high concentrations of β-VLDL (30 μg protein/ml) did not block SREBP-2 processing (Fig. 9C.  lane 2) . In contrast, when the CHO 4-4-19 cells were transfected with cDNAs encoding either wild-type NPC1 or its Q79A mutant version, β-VLDL blocked SREBP-2 processing at concentrations as low as 1 μg protein/ml (Fig.  9D, lanes 4, 11) . All three transfected CHO 4-4-19 cells (mock, NPC1 wild-type, and NPC1 Q79A mutant) responded to 25-HC (Fig 9 C,  lane 3; Fig. 9D, lanes 8 and 15) .
DISCUSSION
The current data reveal a saturable sterol binding site on luminal loop-1 of human NPC1. The importance of this 240-amino acid loop is revealed by its strong sequence conservation in all vertebrate orthologs of NPC1 and in related proteins from eukaryotes as remote as yeast. When isolated as a soluble, secreted protein, this loop appears to form a homodimer as indicated by gel filtration. At saturation, one molecule of cholesterol or 25-HC is bound to each dimer of luminal loop-1. Under the conditions of our in vitro assay, the affinity for 25-HC (K d , 10 nM) was 13-fold higher than the affinity for [ 3 H]cholesterol (K d , 130 nM). Consistent with this difference, 25-HC was an effective competitor of cholesterol binding, whereas cholesterol was a poor competitor for 25-HC binding.
As we observed with full-length NPC1, binding of cholesterol, but not 25-HC to luminal loop-1 was sensitive to the concentration of detergent in the assay. Cholesterol binding was abolished by supramicellar concentrations of a variety of detergents, including uncharged detergents (NP-40 and DDM) and zwitterionic detergents (DHPC and CHAPS) (Fig. 5B) . Of these detergents, CHAPS was the only one that partially reduced binding of 25-HC. We interpret this finding to indicate that cholesterol has a tendency to partition into micelles rather than to bind to luminal loop-1. If manifest within cells, this tendency might be important in regulating the ability of NPC1 to move cholesterol from one membrane compartment to another.
In this regard, it is interesting that NPC2 has been shown to transfer its bound cholesterol to phospholipid liposomes in a reaction that is accelerated by a phospholipid, lysobisphosphatidic acid (28) . This observation was possible because Cheruku, et al. (28) observed that cholesterol binding quenches the tryptophan fluorescence of NPC2. In preliminary studies, we found that 25-HC binding to luminal loop-1 does not alter its tryptophan fluorescence. Other methods will have to be employed to test the ability of luminal loop-1 to transfer its bound sterols to membranes.
In the only previous study of cholesterol binding to NPC1, Ohgami, et al. (41) used a photoactivated analog of cholesterol (7,7-azocholestanol) . They added a radiolabeled version of this compound to intact cells and observed crosslinking to NPC1. There was a marked reduction in crosslinking when the cells expressed a loss-of-function mutant of NPC1 with a substitution in the sterol-sensing domain (P692S). Whether this crosslinking was caused by direct binding to the sterol-sensing domain, or whether this domain played a permissive role, could not be determined from these studies. The sterol specificity of the crosslinking in terms of whether or not the cholesterol interaction was competed by oxysterols was also not determined.
In the current studies, we found evidence that luminal loop-1 is the sole oxysterol-binding site on NPC1, at least under the conditions of our in vitro assays. Thus, a point mutation in luminal loop-1 (Q79A) abolished binding of 25-HC to the soluble luminal loop-1 (Fig. 6A) , and it also abolished binding to full-length recombinant NPC1 (Fig.  8A ). The situation with regard to cholesterol binding is less clear. When produced in soluble luminal loop-1, the Q79A mutation reduced binding of [ (Fig.  6B ), yet this mutation in full-length NPC1 abolished binding of [ (Fig. 8B) . This difference could be attributable to the sensitivity of the cholesterol binding reaction to the presence of detergents. It is possible that the Q79A mutation impairs cholesterol binding to the extent that it becomes more sensitive to the presence of even small amounts of detergent, and that the full-length protein has more detergent bound to it than does the soluble protein. The important question of whether luminal loop-1 is the sole cholesterol binding site on NPC1 will not be resolved until in vitro assays can be performed with NPC1 in a more normal environment, either in situ in isolated membranes or after reconstitution in liposomes.
The difference in the specificity of sterol binding between NPC1 and NPC2 suggests major differences in the sterol binding pocket of the two proteins. Whereas luminal loop-1 of NPC1 and NPC2 both bound [ 3 H]cholesterol with similar affinities, only NPC1 bound [
3 H]25-HC (Fig. 7B) .
Moreover, binding of [ 3 H]cholesterol to NPC2 was inhibited by epicholesterol and cholesteryl sulfate, whereas binding to luminal loop-1 of NPC1 was not inhibited. The crystal structure of cholesteryl sulfate bound to NPC2 provides an explanation for the specificity of NPC2's binding reaction (29) . The cholesterol moiety binds with its hydrophobic side chain deeply embedded in a hydrophobic pocket that molds itself to accommodate the side chain and thus would not be expected to tolerate the presence of a polar hydroxyl, a finding consistent with our experimental data showing that 24-HC, 25-HC, and 27-HC do not bind NPC2 (Fig. 7D) . On the other hand, the 3-hydroxyl of cholesterol is fully exposed to solvent, and therefore the binding would not be disrupted by the α-orientation of this hydroxyl in epicholesterol. The sterol binding site on luminal loop-1 of NPC1 must be quite different. This site must be able to accommodate polar groups on the side chain since the addition of a 25-hydroxyl group increases the affinity of binding by 13-fold. The site must also recognize the 3-hydroxyl on the other end of the cholesterol molecule since binding strongly prefers the β-orientation. It should be possible to define the sterol binding site crystallographically since it is possible to produce large amounts of soluble, secreted luminal loop-1. The major challenge for the future is to define the functional role, if any, of the sterol binding site on luminal loop-1 of NPC1. Sterol binding to this site does not seem to be important for the known function of NPC1 in fibroblasts. Thus, in NPC1-deficient cells 25-HC blocks SREBP cleavage (11) , accelerates the degradation of 3-hydroxy-3-methlglutyl CoA reductasecarrying β-VLDL to activate ACAT and block SREBP-2 processing in mutant CHO cells that lack NPC1 function (Fig. 9) . It should be noted that these latter studies all involved marked overexpression of the Q79A mutant using a strong CMV promoter and thus could be obscuring a sterol-dependent regulatory role for the luminal loop-1. Future studies will need to be done in stably transfected cells expressing wild type and mutant NPC1 under control of a weak promoter.
It is likely that the sterol binding site in luminal loop-1 is essential for some function of NPC1 that is required in vivo, but is not reflected in cultured fibroblasts.
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